Apricitabine

Apricitabine

Clinical data
Routes of administration	Oral
ATC code	none
Legal status
Legal status	Investigational
Pharmacokinetic data
Bioavailability	65 to 80%
Protein binding	< 4%
Metabolism	To apricitabine triphosphate
Elimination half-life	6 to 7 hours (triphosphate)
Excretion	Renal
Identifiers
IUPAC name 4-amino-1-[(2R,4R)-2-(hydroxymethyl)-1,3- oxathiolan-4-yl]pyrimidin-2(1H)-one
CAS Number	160707-69-7 N
PubChem CID	455041
ChemSpider	400685 Y
UNII	K1YX059ML1
ChEMBL	ChEMBL210651 Y
CompTox Dashboard (EPA)	DTXSID60166974
Chemical and physical data
Formula	C8H11N3O3S
Molar mass	229.25 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C1/N=C(/N)\C=C/N1[C@@H]2S[C@@H](OC2)CO
InChI InChI=1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-14-7(3-12)15-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7-/m1/s1 Y Key:RYMCFYKJDVMSIR-RNFRBKRXSA-N Y
NY (what is this?)  (verify)

Apricitabine (INN, codenamed AVX754 and SPD754, sometimes abbreviated to ATC) is an experimental nucleoside reverse transcriptase inhibitor (NRTI) against HIV. It is structurally related to lamivudine and emtricitabine, and, like these, is an analogue of cytidine.